Vectorious Medical Technologies News
17 articles
Edwards Lifesciences completes $497 million acquisition of Israel’s Vectorious | CTech
Edwards Lifesciences, a leading medical device company, has completed the acquisition of Israeli startup Vectorious Medical Technologies for $497 million. This acquisition strengthens Edwards position in heart failure monitoring technology. Vectorious developed the V-LAP system, a minimally invasive sensor for monitoring left atrial pressure, an early indicator of heart failure. The system has shown success in clinical trials, reducing hospital readmissions and improving patient quality of life. This acquisition is part of Edwards strategy to expand its presence in Israel, following its previous acquisition of Involve Biomedical for $300 million. Vectorious, founded in 2011, has raised $35 million and employs 120 people in Israel.
Acquisition
Vectorious Announces VECTOR-HF I Study Confirms Safety and Accuracy of V-LAP In-Heart Sensor for Left Atrial Pressure Management of Heart Failure
Vectorious Begins the VECTOR-HF II Study of its Implantable In-Heart Sensor for Left Atrial Pressure-Guided Patient Self-Management of Heart Failure
Vectorious' in-heart microcomputer wins FDA breakthrough nod
Vectorious Medical Technologies has received FDA breakthrough device designation for its left atrial pressure monitoring device, V-LAP. The device is the first digital, wireless, battery-free device that can communicate from deep within the body. It provides real-time indication of heart failure exacerbation, allowing for improved heart failure management. Vectorious plans to launch a U.S. clinical study in 2022. The breakthrough designation highlights the need for novel monitoring devices for heart failure patients.
CustomersInvestment
שידורי הלב: מחשב זעיר מושתל מדווח מהשטח על מצב החולים
Israeli company Vectorious Medical Technologies has developed a wireless digital computer that can be implanted in the heart to monitor and treat heart failure. The company, founded in 2011, has implanted the device in 18 people so far, with a goal of reaching 45 patients by mid-2020. This should be sufficient for approval in Europe, with FDA research planned for 2022. The company has raised $35 million to date, including $15 million since the start of the coronavirus crisis, and has 40 employees in Tel Aviv.
InvestmentExpand
Reimagining remote care for patients with heart failure
Israeli start-up Vectorious Medical Technologies has developed an implantable remote-monitoring device called V-LAP for heart patients. The device aims to enable accurate, early detection of heart failure symptoms, improve treatment decisions, and reduce healthcare costs. The company received €1.8 million in financing from the EUs Horizon 2020 program in 2018. Vectorious plans to conduct trials in Germany, Italy, Israel, and the UK, with the goal of obtaining CE mark certification in 2021. The company has raised $18.6 million in funding to date and intends to launch its study in the US to obtain FDA approval by 2025. Vectorious is part of the emerging field of bio-convergence and aims to revolutionize medical treatment by combining different technologies and solutions.
CustomersInvestment
This Israeli startup helps predict heart failure before it happens
Israeli healthtech startup Vectorious has developed a wireless and battery-less in-heart microcomputer that provides early detection of heart failure. The device is implanted on the heart and measures left atrial pressure, which is a predictive indication of heart failure. The data-driven device, called V-LAP, allows doctors to remotely manage a patients condition and adjust medication as needed. Vectorious is currently enrolling patients in several countries and plans to initiate an FDA study by 2021. The company has raised over $18.6 million from investors including Fresenius Medical Care, Broadview Ventures, Go Capital, Cleveland Clinic Foundation, and Israeli leading Angel investors.
CustomersPartnersInvestment
https://www.jpost.com/health-science/hillels-tech-corner-vectorious-taking-technology-to-heart-literally-627313
Vectorious Medical Technologies, based in Tel Aviv, has developed the V-LAP sensory implant, a digital, wireless, battery-free device that monitors the hearts left atrial pressure (LAP) to predict heart failure deterioration. The device provides real-time clinical data and AI algorithms to help physicians make informed decisions and provide remote treatment to heart failure patients. Vectorious has raised over $17.5 million from investors and has conducted clinical studies in Europe and Israel. They are expected to launch a clinical study in the US in 2022. The company aims to revolutionize heart failure management by remotely monitoring patients with in-body microsensors, providing accurate data for optimal treatment and improved outcomes.
CustomersInvestment
Computer heart implant aims to aid treatment
A new tiny computer called V-LAP has been developed to help millions of people suffering from heart failure. The device is injected into the body and travels through the veins to the heart, where it opens up and sends data to doctors. This data helps doctors provide better treatments and adjust medicines at an earlier stage. The V-LAP has the potential to significantly improve the quality of care for heart failure patients.
Customers
Vectorious Medical Technologies Announces World`s First In-Heart Microcomputer for Left Atrial Pressure Monitoring
In-Body Microcomputer Could Help Heart Failure Patients Live Longer
Medical technology company Vectorious has developed a pea-sized in-body microcomputer, the V-LAP sensor, to improve the quality of life for heart failure patients. The device sits within the heart and provides real-time data to health professionals. It can detect when pressure in the heart elevates and alert doctors in time. The device is charged remotely via an external chest strap fitted by the patient and can collect and transmit data to doctors based anywhere and at any time. The device has been launched in the U.K. and has been implanted in two British patients so far.
CustomersExpand
Vectorious starts trial of implantable wireless heart monitor
Vectorious Medical Technologies has started a first-in-human trial of its left atrial pressure monitoring device. The trial will enroll up to 30 patients across multiple sites in Germany, Israel, Italy, and the U.K. The V-Lap implantable wireless heart monitor aims to monitor pressure in the hearts left atrium and improve heart failure management. The device is the worlds first digital, wireless, battery-less device that can communicate from deep within the body. Vectorious has received investments from Fresenius Medical Care, Broadview Ventures, GoCapital, and Chinas GEOC, as well as a $2.2 million grant from the European Unions Horizon 2020 R&D program and the Israel Innovation Authority.
Investment
Fresenius put $2m into Vectorious Medical's $10m Series B
Fresenius has invested $2 million in a Series B round for Vectorious Medical Technologies, a cardiac implant company. The round brought in a total of nearly $10 million for Vectorious. The company is developing the V-Lap implantable wireless heart monitor, which monitors pressure in the hearts left atrium. The investment demonstrates Fresenius confidence in the innovative potential of medical products in Israel.
Investment
Israeli heart monitoring co Vectorious raises $9.5m
Israeli medical device company Vectorious Medical Technologies has raised $9.5 million in a Series B financing round led by Broadview Ventures and GEOC. The funds will be used to expand the workforce and conduct clinical trials for marketing approval in Europe. Vectorious has developed V-LAP, a wireless microcomputer for left-atrial monitoring. The company aims to prevent the worsening of heart disease and improve patient quality of life. Vectorious was founded in 2011 and has offices in Tel Aviv and at the Cleveland Clinic.
InvestmentExpand
Miniature implant hopes to bypass heart failure
Vectorious Medical Technologies, a Tel Aviv-based medical technology company, is developing a miniaturised heart implant to tackle cardiovascular disease, which claims almost 2 million lives every year in the EU. The implant, which can predict when a heart failure patients condition is about to worsen, has been tested in large animals and has received approval for an EU clinical study. The study will include 20 patients who will be fitted with the device and monitored daily. If successful, the device could significantly reduce healthcare costs and improve patients quality of life.
InvestmentCustomers
Hope of a New Future for Patients with Heart Failure Using New Implantable Hemodynamic Monitoring Technologies, is Highlighted in New Issue of the Journal of the American College of Cardiology
Cardiac monitoring co Vectorious raises $5m
Israeli medical device company Vectorious Medical Technologies has closed a $5 million financing round. The company will use the proceeds to continue development of their novel cardiac monitoring system for congestive heart failure patients. The system is based on a miniature wireless implant that enables daily readings of left atrial pressure. The company believes their monitoring approach provides an earlier and more specific cardiac indication than existing devices. The financing round included investors such as RadBioMed incubator, private investors, and the Global Cardiovascular Innovation Center.
Investment
